Department of Pharmacy-Pharmaceutical Science, University of Bari Aldo Moro, via Orabona 4, 70125-I, Italy.
Department of Chemical-Toxicological and Pharmacological Evaluation of Drugs, Faculty of Pharmacy, "Catholic University Our Lady of Good Counsel", Tirana, Albania.
CNS Neurol Disord Drug Targets. 2022;21(2):130-149. doi: 10.2174/1871527320666210119095626.
Arachidonic acids and its metabolites modulate plenty of ligand-gated, voltage-dependent ion channels, and metabolically regulated potassium channels including ATP-sensitive potassium channels (KATP). KATP channels are hetero-multimeric complexes of sulfonylureas receptors (SUR1, SUR2A or SUR2B) and the pore-forming subunits (Kir6.1 and Kir6.2) likewise expressed in the pre-post synapsis of neurons and inflammatory cells, thereby affecting their proliferation and activity. KATP channels are involved in amyloid-β (Aβ)-induced pathology, therefore emerging as therapeutic targets against Alzheimer's and related diseases. The modulation of these channels can represent an innovative strategy for the treatment of neurodegenerative disorders; nevertheless, the currently available drugs are not selective for brain KATP channels and show contrasting effects. This phenomenon can be a consequence of the multiple physiological roles of the different varieties of KATP channels. Openings of cardiac and muscular KATP channel subunits, are protective against caspase-dependent atrophy in these tissues and some neurodegenerative disorders, whereas in some neuroinflammatory diseases, benefits can be obtained through the inhibition of neuronal KATP channel subunits. For example, glibenclamide exerts an anti-inflammatory effect in respiratory, digestive, urological, and central nervous system (CNS) diseases, as well as in ischemia-reperfusion injury associated with abnormal SUR1-Trpm4/TNF-α or SUR1-Trpm4/ Nos2/ROS signaling. Despite this strategy being promising, glibenclamide may have limited clinical efficacy due to its unselective blocking action of SUR2A/B subunits also expressed in cardiovascular apparatus with pro-arrhythmic effects and SUR1 expressed in pancreatic beta cells with hypoglycemic risk. Alternatively, neuronal selective dual modulators showing agonist/antagonist actions on KATP channels can be an option.
花生四烯酸及其代谢产物调节大量配体门控、电压依赖性离子通道,以及代谢调节钾通道,包括三磷酸腺苷敏感性钾通道(KATP)。KATP 通道是磺酰脲受体(SUR1、SUR2A 或 SUR2B)和孔形成亚基(Kir6.1 和 Kir6.2)的异源多聚体复合物,同样表达在神经元和炎症细胞的前突触和后突触,从而影响它们的增殖和活性。KATP 通道参与淀粉样蛋白-β(Aβ)诱导的病理学,因此成为治疗阿尔茨海默病和相关疾病的治疗靶点。这些通道的调节可以代表治疗神经退行性疾病的创新策略;然而,目前可用的药物对脑 KATP 通道不具有选择性,并且表现出相反的作用。这种现象可能是由于不同种类的 KATP 通道具有多种生理作用的结果。心脏和肌肉 KATP 通道亚基的开放对这些组织和一些神经退行性疾病中 caspase 依赖性萎缩具有保护作用,而在一些神经炎症性疾病中,通过抑制神经元 KATP 通道亚基可以获得益处。例如,格列本脲在呼吸、消化、泌尿和中枢神经系统(CNS)疾病以及与异常 SUR1-Trpm4/TNF-α或 SUR1-Trpm4/Nos2/ROS 信号相关的缺血再灌注损伤中发挥抗炎作用。尽管这种策略很有前途,但由于其对 SUR2A/B 亚基的非选择性阻断作用,格列本脲可能具有有限的临床疗效,SUR2A/B 亚基也表达在心血管系统中,具有致心律失常作用,而 SUR1 则表达在胰腺β细胞中,具有低血糖风险。或者,具有 KATP 通道激动剂/拮抗剂作用的神经元选择性双重调节剂可能是一种选择。